|Price and Volume|
|52 Week High||9.36|
|52 Week Low||4.35|
|Avg. Daily Vol. (Mil)||1.82|
|Beta (3 year)||1.51|
|Share Related Items|
|Mkt Cap (Mil)||320.71|
|Shares Out (Mil)||59.50|
|LT Debt/ Equity||0.00|
|Total Debt / Equity||0.01|
|Per Share Data|
|Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.|
|225 South Lake Avenue
Pasedena, CA 91101
|Industry : Drugs|
|Sector: Health Care|
|CEO: Dr. Christopher Anzalone|
|Current Month (Mil)||14.18|
|Previous Month (Mil)||14.74|
|Short Interest Ratio (Days)||9.70|
|Return on Equity||n.a.|
|Return on Assets||-61.70|
|Return on Investments||-68.00|
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.
|Rating||Current||1-Mo Ago||2-Mo Ago||3-Mo Ago|
|GET ARWR ANALYST REPORT|